Feature
Patient commentary: the current model has failed
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4568 (Published 04 October 2017) Cite this as: BMJ 2017;359:j4568
- Emma Robertson, leader of Just Treatment
- elizabeth{at}justtreatment.org
The cost of cancer drugs is skyrocketing: prices of cancer drugs increased by 10% every year between 1995 and 2013.1 More and more we’re seeing cancer drugs being priced off the NHS—as is the case with secondary breast cancer drug palbociclib, currently under review after it was rejected by NICE earlier this year because of cost.
Another really hard burden to bear for patients is that so many …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.